eligibility_summary
Eligible: consented, previously untreated CD20+ DLBCL, life expectancy ≥6 mo, IPI 2–5, ECOG 0–2, LVEF ≥50%, adequate counts (Hb ≥9 g/dL without transfusion in prior 7 d, ANC ≥1.0×10^9/L, PLT ≥75×10^9/L). Exclude: contraindications to study drugs, problematic comorbid malignancy, significant cardiovascular disease/abnormal ECG, active infection, AST/ALT ≥2.5×ULN, bilirubin ≥1.5×ULN, CrCl <40 mL/min, latent/active TB, PML history.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06516978 is an open-label, randomized phase 2 trial in untreated CD20+ DLBCL comparing Pola‑RCHP‑X vs RCHOP‑X vs Pola‑RCHP. Drugs/mechanisms (type): polatuzumab vedotin (ADC, targets CD79b on B cells, delivers MMAE microtubule poison), rituximab (anti‑CD20 mAb, B‑cell depletion via ADCC/CDC), cyclophosphamide (alkylating chemo, DNA crosslinking), doxorubicin (anthracycline, topoisomerase II inhibition/free radicals), vincristine (vinca alkaloid, microtubule inhibitor), prednisone (corticosteroid, lympholytic via glucocorticoid receptor), orelabrutinib (small‑molecule BTK inhibitor, blocks BCR signaling), venetoclax (small‑molecule BCL‑2 inhibitor, induces apoptosis), chidamide (small‑molecule selective HDAC inhibitor, epigenetic/immune effects), penpulimab (anti‑PD‑1 mAb, checkpoint blockade), lenalidomide (IMiD, cereblon‑mediated IKZF1/3 degradation, T/NK activation). Targets/pathways: malignant B cells (CD79b, CD20), BCR‑BTK, BCL‑2, HDACs, PD‑1 on T cells, cereblon/IKZF, microtubules, DNA damage/Topo II, glucocorticoid receptor.